{
    "clinical_study": {
        "@rank": "110956", 
        "arm_group": {
            "arm_group_label": "Maintenance Temozolomide + Disulfram", 
            "arm_group_type": "Experimental", 
            "description": "Beginning 4-6 weeks after completion of radiation therapy, patients receive maintenance temozolomide 150-200 mg/m2 PO QD on Days 1-5 every 28 days for 6 months. Disulfiram (dose level 0 = 500 mg PO QD or dose level 1 1000 mg PO QD) on days 1-28. Treatment repeats every 28 days for 6 courses* in the absence of disease progression or unacceptable toxicity.\nNOTE: *Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
        }, 
        "brief_summary": {
            "textblock": "This clinical trial studies disulfiram in treating patients with glioblastoma multiforme\n      (GBM) who have completed radiation therapy with temozolomide. Disulfiram may block some of\n      the enzymes needed for tumor cell growth and improve clinical outcome in GBM patients."
        }, 
        "brief_title": "Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Glioblastoma", 
        "condition_browse": {
            "mesh_term": "Glioblastoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of histologically confirmed GBM (WHO grade IV).\n\n          -  At least 18 years of age.\n\n          -  ECOG performance status of at least 2.\n\n          -  Has received or is in the process of completing a course of definitive radiotherapy\n             of at least 45 Gy with concurrent temozolomide (patient may be registered before\n             completing radiotherapy as long as it is anticipated that s/he will complete at least\n             45 Gy).\n\n          -  Eligible for and planning to receive maintenance temozolomide after completion of\n             definitive radiotherapy plus temozolomide.\n\n          -  Willing to remain abstinent from consuming alcohol while on disulfiram.\n\n          -  Meets the following laboratory criteria:\n\n               -  Absolute neutrophil count \u2265 1,500/mcL\n\n               -  Platelets \u2265 100,000/mcL\n\n               -  Hemoglobin > 9.0 g/dL (transfusion and/or ESA allowed)\n\n               -  Total bilirubin \u2264 2x institutional upper limit of normal (ULN)\n\n               -  AST and ALT < 3 x ULN\n\n               -  Calculated creatinine clearance must be > 60 mL/min (by Cockcroft-Gault)\n\n          -  Females of childbearing potential (defined as a female who is non-menopausal or\n             surgically sterilized) must be willing to use an acceptable method of birth control\n             (i.e., hormonal contraceptive, intra-uterine device, diaphragm with spermicide,\n             condom with spermicide, or abstinence) for the duration of the study.  Should a woman\n             become pregnant or suspect she is pregnant while participating in this study, she\n             must inform her treating physician immediately.\n\n          -  Able to take oral medication.\n\n          -  Able to understand and willing to sign an IRB-approved written informed consent\n             document (legally authorized representative permitted).\n\n        Exclusion Criteria:\n\n          -  Receipt of any other investigational agents within 14 days prior to study enrollment.\n\n          -  Enrolled on another clinical trial testing a novel therapy or drug.\n\n          -  History of allergic reaction to disulfiram.\n\n          -  Treatment with clinically significant cytochromes P450 enzyme inducers, such as\n             phenytoin, phenobarbital, chlordiazepoxide, diazepam, isoniazid, metronidazole,\n             warfarin, amitriptyline within 14 days prior to the first dose of disulfiram. Of\n             note, lorazepam and oxazepam are not affected by the P450 system and are not\n             contraindicated with disulfiram.\n\n          -  Active or severe hepatic, cardiovascular, or cerebrovascular disease, including\n             myocardial infarction within 6 months prior to enrollment, have New York Heart\n             Association (NYHA) Class III or IV heart failure (Appendix B), uncontrolled angina,\n             severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of\n             acute ischemia or active conduction system abnormalities.\n\n          -  History of idiopathic seizure disorder, psychosis or schizophrenia.\n\n          -  Pregnant and/or breastfeeding.  Women of childbearing potential must have a negative\n             pregnancy test within 14 days of initiation of treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01907165", 
            "org_study_id": "201308038"
        }, 
        "intervention": [
            {
                "arm_group_label": "Maintenance Temozolomide + Disulfram", 
                "intervention_name": "Temozolomide", 
                "intervention_type": "Drug", 
                "other_name": "Temodar"
            }, 
            {
                "arm_group_label": "Maintenance Temozolomide + Disulfram", 
                "intervention_name": "Disulfiram", 
                "intervention_type": "Drug", 
                "other_name": "Antabuse"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Disulfiram", 
                "Temozolomide", 
                "Dacarbazine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 12, 2014", 
        "link": {
            "description": "Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine", 
            "url": "http://www.siteman.wustl.edu"
        }, 
        "location": {
            "contact": {
                "email": "jhuang@radonc.wustl.edu,", 
                "last_name": "Jiayi Huang, M.D.", 
                "phone": "314-362-8516"
            }, 
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine"
            }, 
            "investigator": [
                {
                    "last_name": "Albert Kim, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "David Tran, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "A. Craig Lockhart, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Joseph Simpson, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Clifford Robinson, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Todd DeWees, Ph.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pharmacodynamic Study of Proteasome Inhibition by Disulfiram in Patients With Glioblastoma", 
        "overall_contact": {
            "email": "jhuang@radonc.wustl.edu", 
            "last_name": "Jiayi Huang, M.D.", 
            "phone": "314-362-8516"
        }, 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Jiayi Huang, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Degree of proteasome inhibition in peripheral white blood cells and rate of complete inhibition in GBM patients using descriptive statistics", 
            "measure": "Pharmacological effect of disulfiram in GBM patients", 
            "safety_issue": "No", 
            "time_frame": "30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01907165"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The Kaplan-Meier product-limit method will be used.", 
                "measure": "Local tumor control probabilities", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Modeled using the Cox proportional hazard models.", 
                "measure": "Time to tumor progression", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}